Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: November 28, 2022

Details for Patent: 7,157,466

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 7,157,466
Title:Quinazoline ditosylate salt compounds
Abstract:Ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorde4rs characterized by aberrant erbB family PTK activity.
Inventor(s): McClure; Michael Scott (Durham, NC), Osterhout; Martin Howard (Durham, NC), Roschangar; Frank (Glen Allen, VA), Sacchetti; Mark Joseph (Foster City, CA)
Assignee: SmithKline Beecham (Cork) Limited (IE)
Application Number:10/311,678
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,157,466

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,157,466

PCT Information
PCT FiledJune 28, 2001PCT Application Number:PCT/US01/20706
PCT Publication Date:January 10, 2002PCT Publication Number: WO02/02552

International Family Members for US Patent 7,157,466

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 031248 See Plans and Pricing
Austria 353891 See Plans and Pricing
Australia 2001273071 See Plans and Pricing
Australia 2010274106 See Plans and Pricing
Australia 7307101 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.